Challenging indication of cardioverter defibrillator implantation after sudden cardiac arrest in the very young: a case series of catecholaminergic polymorphic ventricular tachycardia secondary to

Calmodulin Case report Catecholaminergic polymorphic ventricular tachycardia Implantable cardioverter-defibrillator Shared decision-making Sudden cardiac death

Journal

European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 05 03 2021
revised: 07 04 2021
accepted: 20 09 2021
entrez: 3 11 2021
pubmed: 4 11 2021
medline: 4 11 2021
Statut: epublish

Résumé

Calmodulinopathy is an emerging group of primary electrical disease with various, severe, and early onset phenotype. Sudden cardiac arrest (SCA)/death can be the first symptom and current medical management seems insufficient to prevent recurrences. Implantable cardioverter-defibrillator (ICD) in the young is challenging and can be harmful. We report the management of two very young boys (aged 3.5 and 5.5 years old) who survived an SCA due to calmodulin mutation responsible of a catecholaminergic polymorphic ventricular tachycardia phenotype. In both case, SCA had an adrenergic trigger. Despite SCA, ICD implantation was denied by the parents. After thorough discussion with the family, the patients were managed with solely betablocker treatment and loop recorder implantation. At last follow-up of 30 and 23 months, respectively, there were no recurrence of any cardiac event. The benefits of ICD implantation at a very young age must be weighed against the risk complication. In the youngest, whom recreative activities are under constant supervision, the decision, jointly made with the parents, could be to postpone ICD.

Sections du résumé

BACKGROUND BACKGROUND
Calmodulinopathy is an emerging group of primary electrical disease with various, severe, and early onset phenotype. Sudden cardiac arrest (SCA)/death can be the first symptom and current medical management seems insufficient to prevent recurrences. Implantable cardioverter-defibrillator (ICD) in the young is challenging and can be harmful.
CASE SUMMARY METHODS
We report the management of two very young boys (aged 3.5 and 5.5 years old) who survived an SCA due to calmodulin mutation responsible of a catecholaminergic polymorphic ventricular tachycardia phenotype. In both case, SCA had an adrenergic trigger. Despite SCA, ICD implantation was denied by the parents. After thorough discussion with the family, the patients were managed with solely betablocker treatment and loop recorder implantation. At last follow-up of 30 and 23 months, respectively, there were no recurrence of any cardiac event.
DISCUSSION CONCLUSIONS
The benefits of ICD implantation at a very young age must be weighed against the risk complication. In the youngest, whom recreative activities are under constant supervision, the decision, jointly made with the parents, could be to postpone ICD.

Identifiants

pubmed: 34729453
doi: 10.1093/ehjcr/ytab393
pii: ytab393
pmc: PMC8557678
doi:

Types de publication

Case Reports

Langues

eng

Pagination

ytab393

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

Heart Rhythm. 2016 Sep;13(9):1905-12
pubmed: 27321244
Pacing Clin Electrophysiol. 2013 Dec;36(12):1532-8
pubmed: 24033753
Heart Rhythm. 2008 Dec;5(12):1755-7
pubmed: 18835225
Europace. 2015 Nov;17(11):1601-87
pubmed: 26318695
Heart Rhythm. 2014 Jan;11(1):58-66
pubmed: 24120999
J Am Coll Cardiol. 2008 Apr 29;51(17):1685-91
pubmed: 18436121
Heart Rhythm. 2006 Dec;3(12):1486-9
pubmed: 17161793
J Cardiovasc Electrophysiol. 2004 Jan;15(1):72-6
pubmed: 15028076
J Am Coll Cardiol. 2018 Oct 2;72(14):1677-1749
pubmed: 29097294
Circ Cardiovasc Genet. 2016 Jun;9(3):259-65
pubmed: 27114410
Pacing Clin Electrophysiol. 2004 Jul;27(7):924-32
pubmed: 15271011
Eur Heart J. 2019 Sep 14;40(35):2964-2975
pubmed: 31170290
Heart Rhythm. 2010;7(2):193-8
pubmed: 20022820
J Cardiovasc Electrophysiol. 2008 Dec;19(12):1319-21
pubmed: 18554199
Circ Arrhythm Electrophysiol. 2015 Jun;8(3):633-42
pubmed: 25713214
Eur Heart J. 2019 Sep 14;40(35):2953-2961
pubmed: 31145795
Am J Cardiol. 2012 Jul 1;110(1):72-6
pubmed: 22481011
Rev Esp Cardiol. 2006 Oct;59(10):1079-80
pubmed: 17125720
Circ Arrhythm Electrophysiol. 2020 Dec;13(12):e008830
pubmed: 33198487
Circ Arrhythm Electrophysiol. 2013 Jun;6(3):579-87
pubmed: 23667268

Auteurs

Alice Maltret (A)

Hôpital Marie Lannelongue-M3C, GHPSJ, Université Paris Saclay, service de cardiologie congénitale, Le Plessis-Robinson, France.

Fatima Azzahrae Benaich (FA)

M3C-Necker, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France.

John Rendu (J)

Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Univ. Grenoble Alpes, Inserm U1216, Grenoble Institut Neurosciences, Grenoble, France.

Véronique Fressart (V)

Groupe Hospitalier Pitié-Salpêtrière, Service de Biochimie Métabolique, Unité de Cardiogénétique et Myogénétique, APHP, Paris, France.

Nathalie Roux-Buisson (N)

Centre Hospitalier Universitaire Grenoble Alpes, Laboratoire de Biochimie et Génétique Moléculaire, Univ. Grenoble Alpes, Inserm U1216, Grenoble Institut Neurosciences, Grenoble, France.

Damien Bonnet (D)

M3C-Necker, Hôpital Universitaire Necker-Enfants Malades, APHP, Paris, France.

Isabelle Denjoy (I)

CNMR, Maladies Cardiaques Héréditaires Rares, Service de cardiologie, Hôpital Bichat, APHP, Paris, France.

Classifications MeSH